Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.66 |
| ▸ | HTR2A | P28223 | 9/20 | 0.61 |
| ▸ | HTR2C | P28335 | 6/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 4/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.54 |
| ▸ | HTR1B | P28222 | 1/20 | 0.54 |
| ▸ | HTR7 | P34969 | 1/20 | 0.54 |
| ▸ | HTR6 | P50406 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34463042 | 1.00 | TAAR1 (0.66) | TAAR1HTR2AHTR2CADRA1AHTR2B | |
| SCHEMBL29473870 | 0.90 | TAAR1 (0.69) | TAAR1HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL1047458 | 0.90 | TAAR1 (0.69) | TAAR1HTR2AHTR2CHTR2BHTR1A | |
| Hydrochloric Acid SCHEMBL26096716 | 0.88 | TAAR1 (0.67) | TAAR1HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL21240834 | 0.87 | TAAR1 (0.83) | TAAR1HTR2AHTR2CADRA1AHTR2B | |
| SCHEMBL20969693 | 0.86 | TAAR1 (0.53) | TAAR1HTR2AHTR2CADRA1AHTR2B | |
| SCHEMBL20767050 | 0.85 | HTR2A (0.50) | TAAR1HTR2AHTR2CHTR2B | |
| SCHEMBL29673199 | 0.85 | HTR2A (0.50) | TAAR1HTR2AHTR2CHTR2B | |
| SCHEMBL20562875 | 0.83 | HTR2A (0.56) | TAAR1HTR2AHTR2CHTR2B | |
| SCHEMBL24163642 | 0.83 | TAAR1 (0.72) | TAAR1HTR2AHTR2CHTR2BHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-08-01 | — | — | US | disclosed |
| EP-3625222-B1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-07-21 | — | — | EP | disclosed |
| US-20200179383-A1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-06-11 | — | — | US | disclosed |
| EP-3625222-A1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2020-03-25 | — | — | EP | disclosed |
| CN-110612296-A | Phenyl derivatives as PGE2 receptor modulators | 爱杜西亚药品有限公司 | 2019-12-24 | — | — | CN | disclosed |
| WO-2018210994-A1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | TAAR1 395/4885HTR2A 234/4885HTR2C 227/4885 |
| US-20200179383-A1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | TAAR1 375/4885HTR2A 225/4885HTR2C 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.